MX2021003302A - Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez. - Google Patents

Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.

Info

Publication number
MX2021003302A
MX2021003302A MX2021003302A MX2021003302A MX2021003302A MX 2021003302 A MX2021003302 A MX 2021003302A MX 2021003302 A MX2021003302 A MX 2021003302A MX 2021003302 A MX2021003302 A MX 2021003302A MX 2021003302 A MX2021003302 A MX 2021003302A
Authority
MX
Mexico
Prior art keywords
gaboxadol
treatment
stuttering
tics
tourette syndrome
Prior art date
Application number
MX2021003302A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2021003302A publication Critical patent/MX2021003302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona el tratamiento del síndrome de Tourette usando gaboxadol o una sal aceptable farmacéuticamente del mismo. Se proporciona el tratamiento de los tics usando gaboxadol o una sal aceptable farmacéuticamente del mismo. Se proporciona el tratamiento de la tartamudez usando gaboxadol o una sal aceptable farmacéuticamente del mismo. Se proporcionan las composiciones terapéuticas que pueden ser usadas para mejorar uno o más síntomas del síndrome de Tourette. Se proporcionan también las composiciones terapéuticas que pueden ser usadas para mejorar uno o más síntomas de los tics. Se proporcionan también las composiciones terapéuticas que pueden ser usadas para mejorar uno o más síntomas de la tartamudez.
MX2021003302A 2018-09-20 2019-09-20 Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez. MX2021003302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862733730P 2018-09-20 2018-09-20
PCT/US2019/052085 WO2020061410A1 (en) 2018-09-20 2019-09-20 Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering

Publications (1)

Publication Number Publication Date
MX2021003302A true MX2021003302A (es) 2021-05-13

Family

ID=69885717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003302A MX2021003302A (es) 2018-09-20 2019-09-20 Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.

Country Status (10)

Country Link
US (2) US10765666B2 (es)
EP (1) EP3833351A4 (es)
JP (1) JP2022501384A (es)
KR (1) KR20210062662A (es)
CN (1) CN112930182A (es)
AU (1) AU2019345312A1 (es)
CA (1) CA3113644A1 (es)
IL (1) IL281512A (es)
MX (1) MX2021003302A (es)
WO (1) WO2020061410A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501384A (ja) 2018-09-20 2022-01-06 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. トゥレット症候群、チックおよび吃音の処置のためのガボキサドールの使用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
US20040087576A1 (en) * 2002-11-05 2004-05-06 Haracz John L. Antimnemonic therapy for hypermemory syndromes
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
WO2004112786A2 (en) 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
WO2005023256A1 (en) 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
BRPI0509210A (pt) 2004-04-02 2007-08-28 Lundbeck & Co As H uso de gaboxadol, e, métodos para tratar função respiratória enfraquecida, e apnéia do sono
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
DE102005004343A1 (de) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
AU2006235318A1 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
PT2083811T (pt) 2006-11-22 2017-01-23 Clinical Res Ass Llc Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2010015037A1 (en) * 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
JP2012501301A (ja) 2008-09-01 2012-01-19 ハー・ルンドベック・アクチエゼルスカベット ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
KR20150029713A (ko) * 2012-07-12 2015-03-18 사이아돈 파마슈티컬스, 인코포레이티드 투렛 증후군의 치료를 위한 융합된 벤즈아제핀
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
MX2016016136A (es) 2014-06-06 2017-07-05 Ovid Therapeutics Inc Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
IL305342A (en) * 2015-07-17 2023-10-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
US20180235942A1 (en) 2015-08-11 2018-08-23 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
WO2017027249A1 (en) 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR20190013737A (ko) * 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들
AU2017311412B2 (en) 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2022501384A (ja) 2018-09-20 2022-01-06 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. トゥレット症候群、チックおよび吃音の処置のためのガボキサドールの使用

Also Published As

Publication number Publication date
EP3833351A4 (en) 2021-10-13
AU2019345312A1 (en) 2021-03-25
EP3833351A1 (en) 2021-06-16
US10765666B2 (en) 2020-09-08
CA3113644A1 (en) 2020-03-26
JP2022501384A (ja) 2022-01-06
KR20210062662A (ko) 2021-05-31
US20200093806A1 (en) 2020-03-26
WO2020061410A1 (en) 2020-03-26
US11090293B2 (en) 2021-08-17
IL281512A (en) 2021-04-29
US20200375960A1 (en) 2020-12-03
CN112930182A (zh) 2021-06-08

Similar Documents

Publication Publication Date Title
NZ761388A (en) Methods of treatment for cystic fibrosis
MX2019011679A (es) Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
MX2021009673A (es) Moduladores de ror-gamma.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018012174A (es) Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2).
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2018004664A (es) Antagonistas de ep4.
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
MX2022001004A (es) Inhibidores de enzimas.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12020552261A1 (en) Proteasome activity enhancing compounds
MX2021001612A (es) Compuestos utiles en terapia del vih.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2020007162A (es) Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
MX2021003302A (es) Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
EA201991373A1 (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)